CompletedNot Applicable

EUS-guided PORtal Vein Sampling for Circulating Tumor Cells in Pancreatic Cancer Patients

Italy23 participantsStarted 2022-05-17

Plain-language summary

The study aims at evaluating the feasibility and safety of EUS-guided Portal Circulation sampling for isolation, enumeration and profiling od Circulating Tumor Cells (CTC) in Pancreatic Cancer patients. Patients undergoing Endoscopic Ultrasound (EUS) for cyto/histological characterization of the neoplasia will receive an additional Fine Needle Aspiration sampling of a branch of the Portal Circulation to obtain a blood sample which will be processed for CTC enrichment, count and characterization.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patient with a pancreatic solid lesion undergoing EUS with a rapid on-site confirmation of a pancreatic ductal adenocarcinoma * patients primarily followed within San Raffaele Institute Exclusion Criteria: * history of active non-pancreatic cancer * coagulopathy (INR \> 1.5; platelets \< 70.000/ul) or use of non-withdrawable anticoagulant or antiplatelet * known history or endosonographic signs of portal hypertension * extensive invasion of portal vein precluding needle maneuvers * pregnancy and breastfeeding

What they're measuring

Proportion of patients with successful aspiration of portal blood

Timeframe: Day 1

Proportion of patients with procedure-related Adverse Events

Timeframe: 30 days

Trial details

NCT IDNCT05247164

SponsorIRCCS San Raffaele

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-10-22

View on ClinicalTrials.gov More Pancreatic Cancer trials